Role of the 26-hydroxylase in the biosynthesis of bile acids in the normal state and in cerebrotendinous xanthomatosis. An in vivo study.

I Björkhem, …, J I Pedersen, S Skrede


On the basis of different in vitro studies, we have previously suggested that the basic metabolic defect in the rare inherited disease cerebrotendinous xanthomatosis (CTX) is a lack of a hepatic mitochondrial C27-steroid 26-hydroxylase, involved in the normal biosynthesis of bile acids (1980. J. Clin. Invest. 65: 1418-1430; 1981. J. Lipid Res. 22: 191-200; 22: 632-640). In the present work, this hypothesis was tested in vivo. One patient with CTX and two control subjects received intravenously a mixture of [4-14C]7 alpha-hydroxy-4-cholesten-3-one and [6 beta-3H]7 alpha,26-dihydroxy-4-cholesten-3-one, steroids believed to be important precursors of chenodeoxycholic acid. The ratio between 14C and 3H in cholic acid and chenodeoxycholic acid isolated from bile of the CTX-patient was approximately 1/40 and 1/60 of those of the control subjects, respectively. Another patient with CTX and one control subject received a mixture of [4-14C]5 beta-cholestane-3 alpha,7 alpha-diol and [1,2-3H]5 beta-cholestane-3 alpha,7 alpha,26-triol, both possible precursors to chenodeoxycholic acid. In this case the 14C/3H ratio in cholic acid and chenodeoxycholic acid from the patient with CTX was 1/10 and 1/15, respectively, compared with that of the control subject. The most likely explanation for these findings is that very little of the 14C-precursors, i.e. without a 26-hydroxyl group, can be converted into cholic acid and chenodeoxycholic acid because of a defect of the 26-hydroxylase step. The results obtained are […]
Role of the 26-Hydroxylase in the Biosynthesis of Bile Acids in the Normal State and in Cerebrotendinous Xanthomatosis

AN IN VIVO STUDY

INGEMAR BJÖRKHED, OLAV FAUSA, GUNNAR HOPEN, HELGE OFTEBRO, JAN I. PEDERSEN, and SVENRE SKREDE, Department of Clinical Chemistry and Research Centre at Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden; Medical Department A and Institute of Clinical Biochemistry, Rikshospitalet, University of Oslo, Medical Department B, Haukeland Hospital, University of Bergen, Institute for Nutrition Research, School of Medicine, University of Oslo, Norway


In the present work, this hypothesis was tested in vivo. One patient with CTX and two control subjects received intravenously a mixture of [4-14C]7α-hydroxy-4-cholesten-3-one and [6β,3H]7α,26-dihydroxy-4-cholesten-3-one, steroids believed to be important precursors of chenodeoxycholic acid. The ratio between 14C and 3H in cholic acid and chenodeoxycholic acid isolated from bile of the CTX-patient was ~1/40 and 1/60 of those of the control subjects, respectively. Another patient with CTX and one control subject received a mixture of [4-14C]5β-cholestan-3α,7α-diol and [1,2-3H]5β-cholestan-3α,7α,26-triol, both possible precursors to chenodeoxycholic acid. In this case the 14C/3H ratio in cholic acid and chenodeoxycholic acid from the patient with CTX was 1/10 and 1/15, respectively, compared with that of the control subject.

The most likely explanation for these findings is that very little of the 14C-precursors, i.e. without a 26-hydroxy group, can be converted into cholic acid and chenodeoxycholic acid because of a defect of the 26-hydroxylase step.

The results obtained are in accord with our previous findings in vitro. The results further underline the importance of the 26-hydroxylase pathway in the normal biosynthesis of cholic acid and chenodeoxycholic acid in man.

INTRODUCTION According to the most common concept, the degradation of the cholesterol side chain in the biosynthesis of bile acids starts with a mitochondrial 26-hydroxylation followed by an oxidation to give a carboxylic acid (1, 2). After further oxidation by introduction of a hydroxyl group in 24-position, propionic acid is cleaved off and the bile acid is obtained. In the biosynthesis of chenodeoxycholic acid, the most likely substrates for the 26-hydroxylase seem to be 5β-cholestan-3α,7α-diol and 7α-hydroxy-4-cholesten-3-one, whereas 5β-cholestan-3α,7α,12α-triol and 7α,12α-dihydroxy-4-cholesten-3-one are likely substrates in the biosynthesis of cholic acid (1–6). In a recent work (7), we showed that the liver of a patient with the rare inherited metabolic disease cerebrotendinous xanthomatosis (CTX)1 was completely devoid of mito-

1 Abbreviations used in this paper: CTX, cerebrotendinous xanthomatosis; GC-MS, gas chromatography—mass spectrometry; HPLC, high-performance liquid chromatography.

Address reprint requests to Dr. Björkhem, Huddinge University Hospital.

Received for publication 14 December 1981 and in revised form 9 September 1982.
chondrial 26-hydroxylase activity. In the liver of this patient there was a considerable accumulation of the above steroids, believed to be major substrates for the mitochondrial 26-hydroxylase (6). In addition a pathway has been described involving a microsomal 25-hydroxylation followed by a 24β-hydroxylation (8, 9). Further oxidation of the 24β,25-dihydroxylated side chain yields acetone and a bile acid. The microsomal 25-hydroxylase has a high specificity towards 5β-cholestan-3α,7α,12α-triol (3), and consequently cholic acid is the major product of this pathway.

The relative importance of the two pathways is controversial. Patients with CTX are known to excrete considerable amounts of 5β-cholestan-3α,7α,12α,25-tetrol and 5β-cholestan-3α,7α,12α,24,25-pentol in bile and feces (10). We have suggested that this excretion is due to the lack of the mitochondrial 26-hydroxylase required for normal bile acid biosynthesis. Accumulation of 5β-cholestan-3α,7α,12α-triol might lead to an exposure of this steroid to the otherwise less active microsomal 25-hydroxylase.

In contrast, Salen et al. have discussed the possibility that the 25-hydroxylase pathway may be the major pathway in the formation of cholic acid in human liver (8, 9). If so, the basic metabolic defect in CTX is a reduced capacity to convert 5β-cholestan-3α,7α,12α,25-tetrol into cholic acid. The authors found a delayed conversion of labeled 5β-cholestan-3α,7α,12α,25-tetrol into cholic acid in vivo (8, 9) and a relatively low 24β-hydroxylation activity in vitro (reduced to one-fourth) in patients with CTX as compared to control subjects (11). Also the conversion of labeled 5β-cholestan-3α,7α,26-trirol and 7α-hydroxy-4-cholesten-3-one into cholic acid and chenodeoxycholic acid in vivo appeared to be impaired in patients with CTX (12).

The reduced conversion of 5β-cholestan-3α,7α,12α,25-tetrol in vivo and in vitro in patients with CTX may be explained by an expanded endogenous pool of steroids, which might dilute and compete with the exogenous labeled steroid administered (cf. ref. 6, 7). The delayed conversion of 5β-cholestan-3α,7α,26-trirol into bile acids found by Salen et al. is unexpected. The large amounts of accumulated bile alcohols may give secondary effects on the liver and obvious signs of liver damage were present in the two patients with CTX whom we have studied.

In the present work we have synthesized 4-14C-labeled 5β-cholestan-3α,7α-diol and 7α-hydroxy-4-cholesten-3-one as well as 3H-labeled 5β-cholestan-3α,7α,26-trirol and 7α,26-dihydroxy-4-cholesten-3-one. 5β-Cholestan-3α,7α-diol or 7α-hydroxy-4-cholesten-3-one were then administered simultaneously with the corresponding 26-hydroxylated steroid both to CTX-patients and to control subjects. The relative conversion into cholic acid and chenodeoxycholic acid was evaluated by measuring the ratio between 14C and 3H in cholic acid and chenodeoxycholic acid isolated from bile. With such an experimental approach, it should be possible to evaluate the importance of introduction of a 26-hydroxyl group in the biosynthesis of bile acids and to obtain valid information even if there is a generally reduced capacity to convert different C27-steroids into bile acids due to impaired liver function.

METHODS

Materials

Clinical. Two sisters, I.J. (born 6 May 1935) and A.F. (born 27 July 1941) with CTX were studied. Detailed records have been published previously (7). By neurological examination during this stay, I.J. was found to be mentally retarded and to have definite neurological dysfunction including ataxia. She was moderately disabled, also because of extensive xanthomatosis. Cerebral computer tomography showed central and cortical atrophy of moderate severity. Laboratory values (normal reference ranges are indicated in a parenthesis): serum total cholesterol 7.2 mmol/liter (3.5–7.5), triglycerides 2.8 mmol/liter (0.6–1.4), ASAT 25 U/liter (13–38), ALAT 16 U/liter (9–29), alkaline phosphatases 168 U/liter (55–195), and GT 29 U/liter (6–26). A.F. was slightly mentally retarded and less disabled than I.J. She had xanthomatosis, but less extensive than the elder sister. Cerebral computer tomography was normal. Laboratory data: serum total cholesterol 8.5 mmol/liter, triglycerides 1.1 mmol/liter, ASAT 42 U/liter, ALAT 58 U/liter, alkaline phosphatases 265 U/liter and GT 30 U/liter.

Needle liver biopsies were obtained from both CTX-patients. In I.J., light microscopy showed slight liver steatosis, and electron microscopy also crystalloid inclusions in the mitochondria. In A.F. severe steatosis and collagenization of Disse's space were observed. Electron microscopy showed similar inclusions as were found in mitochondria from I.J.

Control patient I was G.H. (female, born 12 May 1925). She underwent examinations for a pancreatic tumor that was removed and classified as a malignant "APUD-oma" (APUD, amine precursor uptake and decarboxylation). Control patient III, P.L.I. (male, born 18 December 1950) suffered from irritable colon. Control patient II L.A. (female, born 25 September 1925) suffered from diabetes mellitus and polyneuropathia of unknown cause. No signs of intestinal or liver disease were found in any of these patients and there were normal values for serum total cholesterol, serum triglycerides, alkaline phosphatases, ASAT, ALAT, and total bilirubin.

The ethical aspects of the present study was approved by the ethical board of the Norwegian Council for Science and Medicine.

Role of the 26-Hydroxylase in Bile Acid Biosynthesis

---

2 26-Hydroxylation: This hydroxylation may be a 26-hydroxylation or a 27-hydroxylation (hydroxylation of the 25-pro-B-methyl group or the 25-pro-S-methyl group, respectively). For a more detailed discussion, see the footnote in ref. 7. Because the stereospecificity might be different in different species and with different substrates, we prefer here to denote the α-hydroxylation of the side-chain of the C27-steroids as 26-hydroxylation.
the Humanities, Division for Medical Research. Informed consent was obtained from all patients and in addition from the family of the two CTX-patients.

Preparation of labeled steroids. 4-14C-labeled 7α-hydroxy-4-cholesten-3-one was prepared from 4-14C labeled cholesterol (obtained from Radiochemical Centre, Amsterdam, England) according to a previously described procedure (16). The material was purified by high-performance liquid chromatography (HPLC). The material obtained was pure as shown by thin-layer chromatography, using benzene-ethyl acetate (1:1, vol/vol) as solvent and by gas-liquid chromatography on SE-30 column (as trimethylsilyl ether). The specific radioactivity was 4.2 × 10^6 dpm/mg.

4-14C-Labeled 5β-cholestan-3α,7α-diol was prepared bio-synthetically from the above [4-14C]7α-hydroxy-4-cholesten-3-one by incubation with the cytosolic fraction of a rat liver homogenate under the conditions previously described (17). The degree of conversion varied between 30 and 50% in the various incubations. The product was purified by preparative thin-layer chromatography, using the same conditions as above and by HPLC (15). The material was pure when tested by thin-layer chromatography and gas-liquid chromatography, using the same conditions as above. The specific radioactivity was 4.2 × 10^6 dpm/mg.

1,2-3H-Labeled 5β-cholestan-3α,7α,26-triol and 6β-3H-labeled 7α,26-dihydroxy-4-cholesten-3-one were prepared from [1,2-3H]5β-cholestan-3α,7α-diol and [6β-3H]7α-hydroxy-4-cholesten-3-one, respectively, by incubation with a reconstituted system of cytochrome P-450 from human liver mitochondria followed by purification on HPLC (15). [6β-3H]7α-Hydroxy-4-cholesten-3-one was prepared by the same route as that described for synthesis of [4-14C]7α-hydroxy-4-cholesten-3-one, with the exception that unlabeled cholesterol and 3H-labeled lithium aluminium hydride (obtained from New England Nuclear, Boston, MA) were used in the procedure (18). In the biosynthesis of [1,2-3H]5β-cholestan-3α,7α-diol, [1,2-3H]7α-hydroxy-4-cholesten-3-one was prepared as above with use of [1,2-3H]cholesterol as starting material (obtained from Radiochemical Centre) followed by incubation with rat liver cytosol as above. Both compounds were purified by HPLC (15) before incubation.

The identification of the final products as 5β-cholestan-3α,7α,26-triol and 7α,26-dihydroxy-4-cholesten-3-one was performed by analyzing their trimethylsilyl ethers (20) on gas liquid chromatography—mass spectrometry (GLC-MS), using a 1.5% SE column at 280°C and an LKB 9000 instrument (LKB Instruments Inc., Stockholm, Sweden), equipped with a multiple ion detector. A compound was regarded as identical with a certain authentic standard when the two compounds cochromatographed on HPLC and GLC and contained one or several characteristic ions in common in their mass spectra. This method has been described in detail previously (6, 15, 21). Both compounds were found to be pure and have a specific radioactivity of 42 × 10^6 dpm/mg.

All chemicals and solvents used in the present study were standard commercial high purity materials.

Procedures

Administration of labeled steroids and collection of bile. CTX patients A.F., and control subject G.H. received by intravenous infusion simultaneously [4-14C]5β-cholestan-3α,7α-diol and [1,2-3H]5β-cholestan-3α,7α,26-triol, and her sister I.J., control subject II, I.A., and III, P.L.I. [4-14C]7α-hydroxy-4-cholesten-3-one and [6β-3H]7α,26-dihydroxy-4-cholesten-3-one. Fixed amounts (Table I) of the radioactive labeled steroids were dissolved in 0.5 ml of ethanol, and slowly added under shaking to 30 ml of a sterile human albumin solution (albumin 20%, Kabi AB, Stockholm, Sweden). The solution was passed through a Millex 0.22-μm

| Table I |

| Percentage of 3H-Activity in Ether Extract Recovered in Bile Acids, and 14C/3H Ratios in Bile Acids Isolated from the Control Subjects and the CTX Patients |
|---|---|
| | Cholic acid | Cholesterol:cholesterol acid | Cholic acid | Cholesterol:cholesterol acid |
| Bile from control subjects given [6β-3H]7α,26-dihydroxy-4-cholesten-3-one + [4-14C]7α-hydroxy-4-cholesten-3-one* | 6.7 | 23 | 1.53 | 0.38 |
| Control II | 11 | 33 | 1.38 | 0.39 |
| Control III | 6.7 | 23 | 1.53 | 0.38 |
| Bile from CTX-patient (I.J.) given [6β-3H]7α,26-dihydroxy-4-cholesten-3-one + [4-14C]7α-hydroxy-4-cholesten-3-one | 2.3 | 43.3 | 0.032 | 0.006 |
| Bile from control subject I given [1,2-3H]5β-cholestan-3α,7α,26-triol + [4-14C]7α-hydroxy-cholesten-3α,7α-diol* | 55 | 34 | 0.09 | 0.10 |
| Bile from CTX-patient (A.F.) given [1,2-3H]5β-cholestan-3α,7α,26-triol + [4-14C]5β-cholestan-3α,7α-diol | 12 | 51 | 0.06 | 0.004 |

* The 14C/3H in this material was 0.80. The total disintegrations per minute given was 3.06 × 10^6 with respect to 3H and 2.47 × 10^6 with respect to 14C.

† The 14C/3H in this material was 0.22. The total disintegrations per minute given was 1.45 × 10^6 with respect to 3H and 0.32 × 10^6 with respect to 14C.

I. Björkhem, O. Fausa, G. Hopen, H. Oftedro, J. I. Pedersen, and S. Skrede
filter (Millipore Corp., Bedford, MA). A fat- and protein-rich meal (to promote gallbladder emptying) was given 17 h before the duodenal intubation, and the infusion of precursors was performed (in less than 30 min) 3 h after the meal. After the infusion, the patients fasted until after sampling of duodenal contents. Duodenal intubation was performed with a Lagerlöf double-lumen tube under fluoroscopic control. Contamination by gastric contents was avoided by separate aspiration. Duodenal contents were collected quantitatively by intermittent suction and collected on ice in 30-min periods. After an initial basic aspiration period of 20 min, gall bladder contraction was promoted by intravenous injection of cholecystokinin (1 clinical U/kg body wt). The sampling period then lasted for 60 min (90 min in I.J., who was cholecystectomized). The amount of bile obtained varied from 82 to 410 ml.

Isolation and analysis of bile acids. Aliquots (10–30%) of the bile portions were hydrolyzed in alkali, extracted, methylated, and subjected to preparative thin-layer chromatography. The different chromatographic zones were visualized by exposure to iodine vapor (22). The radioactivity in aliquots of the material eluted from the different zones of the chromatoplate was measured with an Intertechnique SL 30 liquid scintillation spectrometer, using Luma gel (LUMAC, BV Netherlands) as scintillation fluid. Under the conditions employed, the counting efficiency was 71% for $^{14}$C and 49% for $^3$H. The material in the chromatographic zone corresponding to methyl ester of chenodeoxycholic acid was rechromatographed in the same thin-layer chromatographic system as above, and the purity of the isolated material was ascertained by GLC of the trimethylsilyl ether derivative using an SE-30 column. The material in the chromatographic zone corresponding to cholic acid was diluted with 50–100 mg of unlabeled methyl ester of cholic acid and the mixture was recrystallized three times. The radioactivity in the purified methyl ester of chenodeoxycholic acid and in the recrystallized methyl ester of cholic acid was then measured as above. Under the conditions employed, no corrections for quenching were found to be necessary.

RESULTS

Conversion of [4-14C]7α-hydroxy-4-cholesten-3-one and [6β-3H]7α,26-dihydroxy-4-cholesten-3-one into bile acids. After administration of the above mixture to the two control subjects (L.A. and P.L.I.), ~17 and 75%, respectively, of the administered $^3$H activity and ~28 and 73%, respectively, of the administered $^{14}$C activity was recovered in the ether extract of the hydrolyzed bile sample collected. The lower recovery of bile from patient L.A. may have been due to an unfavorable position of the Lagerlöf tube. The percentage of the $^3$H activity in cholic acid and chenodeoxycholic acid recovered in the ether extract is given in Table I. In addition to cholic acid and chenodeoxycholic acid, radioactivity was found in other fractions, the identity of which was not investigated. After further purification of the chenodeoxycholic acid fraction and crystallization of the cholic acid fraction to constant specific radioactivity, the ratio between $^{14}$C and $^3$H was determined. This ratio was ~1.5 in the cholic acid fraction and ~0.4 in the chenodeoxycholic acid fraction from both control subjects (Table I).

After administration of the same mixture to the CTX-patient (I.J.), ~73% of the administered $^3$H activity and ~9% of the administered $^{14}$C activity was recovered in the ether extract of the hydrolyzed bile sample collected. After purification and crystallization as above, the ratio between $^{14}$C and $^3$H was found to be ~0.03 in the cholic acid fraction and ~0.006 in the chenodeoxycholic acid fraction (Table I). These findings indicate a much less efficient conversion of the non-26-hydroxylated precursor into the primary bile acids than of the 26-hydroxylated precursor.

Conversion of [4-14C]5β-cholestan-3α,7α-diol and [1,2-3H]5β-cholestan-3α,7α,26-triol into cholic acid and chenodeoxycholic acid. After administration of the above mixture to the control subject, ~70% of the $^3$H activity and ~42% of the $^{14}$C activity was recovered in the ether extract of the hydrolyzed bile sample collected. The percentage of the $^3$H activity in the ether extract recovered in cholic acid and chenodeoxycholic acid is given in Table I. After purification and crystallization, the ratio between $^{14}$C and $^3$H was found to be ~0.7 in the cholic acid fraction and ~0.10 in the chenodeoxycholic acid fraction (Table I).

After administration of the same mixture to the CTX-patient (A.F.), ~67% of the $^3$H activity and ~19% of the $^{14}$C activity was found in the ether extract of the hydrolyzed bile acid sample collected. The fraction of the $^3$H activity in the ether extract recovered in cholic acid and chenodeoxycholic acid is given in Table I. After purification and crystallization, the ratio between $^{14}$C and $^3$H was found to be ~0.06 in the cholic acid fraction and ~0.004 in the chenodeoxycholic acid fraction (Table I). Again, these findings indicate a much less efficient conversion of the non-26-hydroxylated precursor.

The essential results of the in vivo experiments are also summarized in Fig. 1.

DISCUSSION

In previous in vitro studies we have presented evidence that the metabolic defect in CTX most probably is a lack of hepatic mitochondrial C27-steroid 26-hydroxylase (6, 7, 21). If the 26-hydroxylase is important in the normal biosynthesis of bile acids and this enzyme is defective in CTX, one would expect 26-hydroxylated precursors to be rapidly converted into primary bile acids in patients with CTX as well as in control subjects. In the present in vivo study this was also found to be the case. Thus, the conversion of $^3$H-labeled 26-hydroxylated precursors into cholic acid + chenodeoxycholic acid was efficient in the CTX-patients as well as in the control subjects. In particular, the recovery in bile as chenodeoxycholic acid of the $^3$H-labeled 26-hydroxylated precursors was about the
FIGURE 1 Results of the in vivo investigations with the double-labeled steroids. For details see Results.

same in the CTX patients as in the controls. These results are at variance with those of Salen et al. (11, 12), who reported that the in vivo conversion of several 26-hydroxylated intermediates into primary bile acids was delayed by ~24 h in CTX patients compared with control subjects. Our data showed, however, that the ratio between $^3$H-activity in chenodeoxycholic and cholic acid was higher in the patients with CTX than in the controls (Table I). The explanation may be that in the biosynthesis of chenodeoxycholic acid in patients with CXT there is almost no dilution of the exogenously administered 26-hydroxylated precursors with endogenous precursor. In the biosynthesis of cholic acid, on the other hand, there will be a competition for the 12α-hydroxylase because of increased amounts of endogenous substrates (6). Due to this competition, more of the 26-hydroxylated precursor may be channeled into the pathway leading to chenodeoxycholic acid. If there is a block in the 26-hydroxylase pathway, 5β-cholestan-3α,7α-diol and 7α-hydroxy-4-cholesten-3-one can be expected to be converted into the primary bile acids considerably less efficiently than the corresponding 26-hydroxylated steroids. This was also found to be the case. Under the conditions employed, the conversion of the non-26-hydroxylated precursors in the CTX patients was reduced with a factor of 10 and 40, respectively, in the biosynthesis of cholic acid and 20 and 60, respectively, in the biosynthesis of chenodeoxycholic acid.

In the normal liver there is a very rapid conversion of an administered precursor into bile acids, and it has been shown in bile fistula patients that the conversion is essentially complete after only one passage through the liver (23–25). In view of this, the ratio between $^{14}$C- and $^3$H-activity (from the non-26-hydroxylated and the 26-hydroxylated precursor respectively) recovered in cholic acid and chenodeoxycholic acid.
formed in the control subjects is not likely to be changed with time. In the CTX-patients, however, there is probably a primary conversion of $^{14}C$-labeled 5β-cholestan-3α,7α-diol and 7α-hydroxy-4-cholesten-3-one into the 25-hydroxylated pentols and tetrols, which are then slowly converted into cholic acid and possibly, to a small extent, also into chenodeoxycholic acid. Thus, the ratio between $^{14}C$ and $^3$H in the primary bile acids in the CTX-patients may increase with time. In view of this, even more drastic differences between the CTX-patients and the control patients could have been obtained if the bile samples had been taken earlier after the administration, and less drastic differences could have been obtained if the samples had been taken later after the administration. Conclusions can thus be drawn from a single ratio determination only if marked differences are obtained. In the present experiments marked differences were in fact observed in the bile collected at a time interval of 14 h after the infusion. By that time all intermediates would normally be converted into bile acids and excreted in the bile (23–24) and the marked reduction in the $^{14}C$/$^3$H ratio observed in the CTX patients as compared with the controls, must reflect a defective conversion of the $^{14}C$-labeled, non-26-hydroxylated precursors.

Introduction of a 26-hydroxyl group in 7α-hydroxy-4-cholesten-3-one and 5β-cholestan-3α,7α-diol was found to increase the conversion into chenodeoxycholic acid in the control subjects with a factor of $\approx$2 (the $^{14}C$/$^3$H ratio was reduced by a factor of 2). This is in accordance with the previous finding that these 26-hydroxylated steroids are efficient precursors to chenodeoxycholic acid in vivo (1, 4, 25). In the biosynthesis of cholic acid, however, the presence of a 26-hydroxyl group reduced the biosynthesis with a factor of $\approx$50 and 75%, respectively, indicating that the 12α-hydroxyl group is introduced more easily before the 26-hydroxyl group. Both these experiments are in accord with previous concepts with respect to the major pathway in the biosynthesis of cholic acid and chenodeoxycholic acid (1, 2).

The distribution of $^{14}C$-activity from 5β-cholestan-3α,7α-diol into cholic acid in the control subject was higher than could be expected, and the corresponding distribution into chenodeoxycholic acid was lower. According to current concepts 5β-cholestan-3α,7α-diol should preferably be converted into chenodeoxycholic acid. On the other hand, individual variations may occur in the present type of in vivo experiments, and the findings obtained do not affect the general conclusions from the experiment.

In the present experiments, more marked differences were found with 7α-hydroxy-4-cholesten-3-one and 7α,26-dihydroxy-4-cholesten-3-one than with 5β-cholestan-3α,7α-diol and 5β-cholestan-3α,7α,26-triol. It should be pointed out that different CTX-patients with different liver pathology were studied in the two sets of experiments, and thus individual variations may occur. In any case both sets of studies give rise to the same general conclusion.

There are several pitfalls in studies in vivo with labeled precursors. Some of the difficulties can be reduced with the present experimental approach, using two different precursors (with different labels) that reach the liver simultaneously. With the technique used, the errors and inconveniences related to estimation of absolute rates of synthesis could be avoided. The present results are in accordance with the contention that the basic metabolic defect in CTX is a lack of the 26-hydroxylase. When taken together with the in vitro data (6, 7) and other in vivo data (4, 23, 26), the present work also gives strong support for the concept that the 26-hydroxylase pathway is most important in the normal synthesis of bile acids.

ACKNOWLEDGEMENTS

The skillful technical assistance of Miss Anita Lövgren, Mrs. Kirsti Haug, and Mr. Manfred Held is gratefully acknowledged. This work was supported by the Swedish Medical Research Council (project 05X-3141) and by the Norwegian Council for Science and the Humanities.

REFERENCES